Validation of the Azeri version of the Pediatric Epilepsy Side Effects Questionnaire
| Autor: | Garaybayli Garay, Salayev Kamran, Magalov Sharif |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Psychometrics Audiology 03 medical and health sciences Epilepsy 0302 clinical medicine Quality of life Surveys and Questionnaires Internal consistency Humans Medicine 030212 general & internal medicine Child Pediatric epilepsy business.industry Construct validity Mean age General Medicine Strengths and Difficulties Questionnaire medicine.disease Caregivers Child Preschool Pediatrics Perinatology and Child Health Anticonvulsants Female Neurology (clinical) business 030217 neurology & neurosurgery PESQ |
| Zdroj: | Child's Nervous System. 35:2379-2383 |
| ISSN: | 1433-0350 0256-7040 |
| Popis: | Long-lasting use of antiepileptic drugs in children with epilepsy negatively influences their quality of life and compliance. The purpose of this study was validation of the Azeri version of the Pediatric Epilepsy Side Effects Questionnaire (PESQ). We collected the PESQ from caregivers of children with epilepsy. In order to screen for comorbid behavioral and emotional problems, the Strengths and Difficulties Questionnaire (SDQ) was used. Demographic and medical data were collected through patient charts. We conducted factor analysis and assessed internal consistency and construct validity of the PESQ. Caregivers of 120 patients with different epileptic syndromes completed the PESQ (age range 2–18; mean age 9.8 ± 4.0; male 56.7%; polytherapy 24%). The factor loading in the principal component analysis confirmed five-factor structure of the PESQ. The internal consistency coefficient of the total side effects scale of the PESQ was strong (0.86). Children receiving polytherapy showed higher scores on all subscales and the total score of the PESQ, supporting its construct validity. The total scores of the PESQ and the SDQ strongly correlated. The PESQ can be used as a reliable and valid measure assessing antiepileptic drug side effects across the epilepsy spectrum. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink